Abstract 179P
Background
Exercise training reduces tumour growth by increasing tumour-infiltrating T cell density in preclinical models. However, it remains unknown whether exercise training can modify intratumoural T cells in humans. Objective: To compare the effects of exercise training intervention versus control on human prostate intratumoural T cell density.
Methods
This study is a secondary analysis of a randomised controlled trial. We randomly allocated men (age >18 years) with treatment-naïve localized prostate cancer scheduled to radical prostatectomy 2:1 to exercise training intervention or control. The exercise intervention consisted of supervised, high-intensity interval bicycling four times per week from the time of randomization until prostatectomy. Intratumoural CD3+ and CD8+ T cell densities in diagnostic biopsies and post-surgical prostatectomy specimens were quantified using immunohistochemistry. Between-group differences in changes from baseline to follow-up were estimated using constrained baseline linear mixed-effect models.
Results
A total of 30 participants were included (exercise intervention, n=20; control, n=10). We found no between-group differences in changes in CD3+ (mean difference [95% Cis]: –17 [–185; 150] cells/mm2) or CD8+ (mean difference [95% CI]: –16 [–206;172] cells/mm2) T cells. Additionally, we found no statistically significant correlations between changes in T cell density and the number of attended exercise training sessions or changes in maximal oxygen consumption.
Conclusions
In this secondary analysis of a randomised controlled trial, we found no impact of exercise training on tumour-infiltrating CD3+ and CD8+ T cell density in human prostate cancer.
Clinical trial identification
Local Ethics Committee of the Capital Region of Denmark (H-18020711). All participants provided informed consent before performing any study-related procedures, and the study was preregistered at www.clinicaltrials.gov (NCT03675529).
Legal entity responsible for the study
The authors.
Funding
TrygFonden and the Lundbeck Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract